8,11-DICHLORO-5,11-DIHYDRO[1]BENZOXEPINO[4,3-b]PYRIDINE | 140937-52-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噁庚英
• 英文名称: 8,11-DICHLORO-5,11-DIHYDRO[1]BENZOXEPINO[4,3-b]PYRIDINE
• 英文别名: 8,11-dichloro-5,11-dihydro-[1]benzoxepino[4,3-b]pyridine
• CAS: 140937-52-6
• 化学式: C₁₃H₉Cl₂NO
• 分子量: 266.127
• InChiKey: LIDTZQPAROECNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2(R)-2-((3S)-3-((4-methylimidazole)methyl)carbonyl)piperazine 、 8,11-DICHLORO-5,11-DIHYDRO[1]BENZOXEPINO[4,3-b]PYRIDINE 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成 [(2R)-4-(8-chloro-5,11-dihydro-[1]benzoxepino[4,3-b]pyridin-11-yl)piperazin-2-yl]-[(3S)-3-[(4-methylimidazol-1-yl)methyl]piperidin-1-yl]methanone
  参考文献：
  名称：

  WO2006/65828

  摘要：

  公开号：
• 作为产物：
  描述：

  8-CHLORO-5,11-DIHYDRO[1]BENZOXEPINO[4,3-B]PYRIDIN-11-ONE 在 sodium tetrahydroborate 、 氯化亚砜 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 3.17h， 生成 8,11-DICHLORO-5,11-DIHYDRO[1]BENZOXEPINO[4,3-b]PYRIDINE
  参考文献：
  名称：

  Inhibitors of farnesyl protein transferase. synthesis and biological activity of amide and cyanoguanidine derivatives containing a 5,11-dihydro[1]benzthiepin, benzoxepin, and benzazepin [4,3-b]pyridine ring system

  摘要：

  Bioisosteric replacement of the C-6 carbon atom in piperidine I and piperazine II with S, O, and N heteroatoms is described. Amide and cyanoguanidine derivatives of these compounds were evaluated in vitro and found to be good inhibitors of farnesyl-protein transferase. An improved method of preparing the 5,11-dihydro-[1]-benzthiepin nucleus 6 was accomplished in high yield and with excellent regioselectivity using an AlCl3 melt protocol. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00439-9

文献信息

• Benzopyrido piperidylidene compounds, compositions, methods of
  申请人：Schering Corporation

  公开号：US05430032A1

  公开（公告）日：1995-07-04

  Disclosed is a compound of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein: R is selected from the group consisting of: H, Cl, Br, F, and I; T represents C or N with the dotted line attached to T representing a double bond when T is C and being absent when T is N; and X represents O or S with the proviso that T is N when X is O. Also disclosed is a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier. Further disclosed is a method of treating asthma, allergy and/or inflammation comprising administering to a mammal in need of such treatment an anti-asthmatic, anti-allergic and/or an anti-inflammatory, respectively, effective amount of a compound of Formula I.

  揭示的是Formula I的化合物：##STR1##或其药学上可接受的盐或溶剂，其中：R选自以下组：H、Cl、Br、F和I；T代表C或N，当T为C时，与T连接的虚线表示双键，当T为N时则不存在；X代表O或S，但T为N时X为O。还揭示了一种包括Formula I的化合物和药学上可接受的载体的药物组合物。进一步揭示了一种治疗哮喘、过敏和/或炎症的方法，包括向需要此类治疗的哺乳动物分别给予Formula I的化合物的抗哮喘、抗过敏和/或抗炎症有效量。
• Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and
  申请人：Schering Corporation

  公开号：US05422351A1

  公开（公告）日：1995-06-06

  Bis-benzo or benzopyrido piperidene, piperidylidene and piperazine compounds of the formula: ##STR1## and pharmaceutically acceptable salts thereof are disclosed, wherein Z represents --(C(R.sup.a).sub.2).sub.m --Y--(C(R.sup.a).sub.2).sub.n -- or ##STR2## The compounds of Formula I possess anti-allergic and anti-inflammatory activity. Methods for preparing and using the compounds are also described.

  本发明揭示了一种具有以下结构的双苯或苯并吡啶哌啶烯，哌啶基亚甲基和哌嗪类化合物的药用盐：其中Z代表--(C(R^a)_2)_m--Y--(C(R^a)_2)_n--或##STR2##。式I的化合物具有抗过敏和抗炎活性。还描述了制备和使用这些化合物的方法。
• Tricyclic compounds having activity as RAS-FPT inhibitors
  申请人：Schering Corporation

  公开号：US06130229A1

  公开（公告）日：2000-10-10

  Compounds of Formula I: ##STR1## wherein: X.sup.1 is hydrogen, halogen, CF.sub.3, nitro, NH.sub.2 or lower alkyl; each X.sup.2 is independently selected from the group consisting of hydrogen, halogen, lower alkoxy and lower alkyl; n is 1 or 2; Y is selected from the group consisting of S(O).sub.p, O, and NR.sup.5, wherein p is 0, 1 or 2, and R.sup.5 is hydrogen, alkyl, aryl, cycloalkyl, loweralkoxycarbonyl, aminocarbonyl or acyl; R.sup.1 and R.sup.2, which may be the same or different, are selected from the group consisting of hydrogen and lower alkyl groups, or taken together can form an oxygen atom when Y is NR.sup.5 ; A . . . is C=, CH-- or N--; R is --CZ--Y.sup.1 --Y.sup.2 --R.sup.3, wherein: Z is O, =CH--CN, or =N--CN; one of Y.sup.1 and Y.sup.2 is a bond, --CO--, O, S, or --NR.sup.4 --, and the other is (CH.sub.2).sub.m, where m is 0 or an integer of 1 to 4, and R.sup.4 is H or alkyl, with the proviso that when Z is O and m is 0 then Y.sup.1 or Y.sup.2 is selected from --CO--, O, S, or --NR.sup.4 ; R.sup.3 is aryl, heteroaryl or heterocycloalkyl, with the proviso that R.sup.3 can also be lower alkyl when Z is =N--CN; and their pharmaceutically acceptable acid addition salts; have activity as Ras-FPT inhibitors. They can be used, e.g., in pharmaceutical compositions, for inhibiting the abnormal growth of cells and for inhibiting proliferative diseases. Processes for their preparation, and useful intermediates, are also disclosed.

  化合物的公式I：##STR1## 其中：X.sup.1为氢、卤素、CF.sub.3、硝基、NH.sub.2或低级烷基；每个X.sup.2独立地选自氢、卤素、低级烷氧基和低级烷基的群；n为1或2；Y选自S（O）.sub.p、O和NR.sup.5的群，其中p为0、1或2，R.sup.5为氢、烷基、芳基、环烷基、低级烷氧羰基、氨基羰基或酰基；R.sup.1和R.sup.2，可以相同也可以不同，选自氢和低级烷基，或者当Y为NR.sup.5时，它们可以连在一起形成一个氧原子；A . . . 为C=、CH-或N-；R为--CZ--Y.sup.1--Y.sup.2--R.sup.3，其中：Z为O、=CH-CN或=N-CN；Y.sup.1和Y.sup.2中的一个为键、--CO--、O、S或--NR.sup.4--，另一个为（CH.sub.2）.sub.m，其中m为0或1到4的整数，R.sup.4为H或烷基，但当Z为O且m为0时，Y.sup.1或Y.sup.2选自--CO--、O、S或--NR.sup.4；R.sup.3为芳基、杂芳基或杂环烷基，但当Z为=N-CN时，R.sup.3也可以是低级烷基；它们的药学上可接受的酸盐具有Ras-FPT抑制剂的活性。它们可以用于制备制药组合物，用于抑制细胞的异常生长和抑制增殖性疾病。本文还公开了它们的制备方法和有用的中间体。
• Benzopyrido piperidylidene compounds as PAF antagonists
  申请人：SCHERING CORPORATION

  公开号：EP0524784A1

  公开（公告）日：1993-01-27

  Disclosed is a compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: R is selected from the group consisting of: H, Cl, Br, F, and I; T represents C or N with the dotted line attached to T representing a double bond when T is C and being absent when T is N; and X represents O or S with the proviso that T is N when X is O. Also disclosed is a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier. Further disclosed is a method of treating asthma, allergy and/or inflammation comprising administering to a mammal in need of such treatment an anti-asthmatic, anti-allergic and/or an anti-inflammatory, respectively, effective amount of a compound of Formula I.

  公开了一种式 I 的化合物： 或其药学上可接受的盐或溶液，其中R 选自以下组成的组H、Cl、Br、F 和 I；T 代表 C 或 N，当 T 为 C 时，T 上的虚线代表双键，当 T 为 N 时，不代表双键；X 代表 O 或 S，但当 X 为 O 时，T 为 N。 还公开了一种药物组合物，它包含式 I 的化合物和药学上可接受的载体。 进一步公开了一种治疗哮喘、过敏和/或炎症的方法，包括向需要治疗的哺乳动物分别施用有效量的式Ⅰ化合物来抗哮喘、抗过敏和/或抗炎。
• TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS
  申请人：SCHERING CORPORATION

  公开号：EP1021448B1

  公开（公告）日：2003-05-02